

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

COALITION FOR AFFORDABLE DRUGS VII LLC,  
Petitioner,

v.

POZEN INC.,  
Patent Owner.

---

IPR2015-01680  
Patent 8,852,636

---

**PETITIONER'S EXHIBIT LIST**

Pursuant to 37 C.F.R. § 42.63(e), Petitioner submits this current list of exhibits.

<b>Exhibit No.</b>	<b>Description</b>
1001	U.S. Patent No. 8,852,636 (“the ’636 Patent”)
1002	File History of the ’636 Patent, U.S. Patent App. No. 14/045,156 (“the ’156 Application”)
1003	Declaration of Leon Shargel, Ph.D., R.Ph.
1004	U.S. Patent No. 5,204,118 (“Goldman”)
1005	“Remington’s Pharmaceutical Sciences,” Alfonso R. Gennaro, et al., Mack Publ’g Co., Seventeenth Edition, (1985) (“Remington”)
1006	U.S. Patent No. 5,698,225 (“Gimet”)
1007	U.S. Patent No. 5,714,504 (“Lindberg”)
1008	U.S. Patent No. 6,183,779 (“Ouali”)
1009	U.S. Patent No. 6,926,907 (“the ’907 Patent”)
1010	Certificate of Correction for the ’907 Patent (December 25, 2007)
1011	“Esomeprazole Provides Improved Acid Control vs. Omeprazole in Patients with Symptoms of Gastro-Oesophageal Reflux Disease,” T. Lind, et al., Alimentary Pharmacology & Therapeutics, Vol. 14, Issue 7 (July 2000) (“Lind”)
1012	U.S. Patent No. 4,757,060
1013	“The Mechanism of Action of Aspirin,” J.R. Vane, et al., Pergamon (June 15, 2003)
1014	G.B. Patent No. 1211134
1015	“Drug-Induced Peptic Ulcer Disease,” Valerie Vella, Journal of the Malta College of Pharmacy Practice, Issue 10 (2005)

Exhibit No.	Description
1016	"Goodman & Gilman's The Pharmacological Basis of Therapeutics," Joel G. Hardman, et al., McGraw-Hill Publ'g Co., Ninth Edition (1996)
1017	"Upper Gastrointestinal (GI) pH in Young, Healthy Men and Women," Jennifer B. Dressman, et al., Pharmaceutical Research, Vol. 7, No. 7 (July 1990)
1018	"Effect of Orally Administered Prostaglandin E <sub>2</sub> and its 15-Methyl Analogues on Gastric Secretion," S. M. M. Karim, et al., British Med. Journal (Jan. 20, 1973)
1019	"Tagamet: The Discovery of Histamine H <sub>2</sub> -Receptor Antagonists," SmithKlein Beecham Pharm., Am. Chem. Soc. (Nov. 24, 1997)
1020	"Inhibition of Gastric (H <sup>+</sup> + K <sup>+</sup> )-ATPase by the Substituted Benzimidazole Picoprazole," B. Wallmark, et al., Biochimica et Biophysica Acta, Vol. 728, Issue 1 (Sept. 2, 1983)
1021	U.S. Patent No. 4,255,431
1022	Notice of Final Determination, In re: Patent Term Extension for U.S. Patent No. 6,143,771 (July 28, 2005)
1023	"Drug Discovery: Practices, Processes, and Perspectives," Jie Jack Li, et al., John Wiley & Sons (Apr. 3, 2013)
1024	"Prevention of the Gastrointestinal Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs," Gregor J.E. Brown, et al., Drug Safety, Vol. 21, Issue 6 (Dec. 21, 1999)
1025	U.S. Patent App. Pub. No. 2002/0045184 ("Chen")
1026	"Management of NSAID-Related Gastrointestinal Mucosal Injury," Adam F. Barrison, et al., Inflammopharmacology, Vol. 7, No. 3 (Sept. 1999)

Exhibit No.	Description
1027	“Prevention of NSAID-Induced Gastroduodenal Ulcers,” A. Rostom, et al., Cochrane Database of Systematic Reviews, Issue 4 (2002)
1028	“Abolition by Omeprazole of Aspirin Induced Gastric Mucosal Injury in Man,” T. K. Daneshmend, et al., Gut, Vol. 31, Issue 5 (May 1990)
1029	U.S. Patent No. 6,319,519
1030	U.S. Patent No. 6,365,184 (“Depui”)
1031	VIMOVO <sup>®</sup> (Naproxen and Esomeprazole Magnesium) Tablets, Horizon Pharma, <a href="http://www.horizonpharma.com/vimovo/">http://www.horizonpharma.com/vimovo/</a> (last visited May 9, 2015)
1032	Horizon Pharma plc 2014 Irish Statutory Accounts, Horizon Pharma Public Limited Company (Apr. 9, 2015)
1033	Shargel Walmart Receipts
1034	Int’l Patent Pub. No. WO 98/54171
1035	U.S. Patent No. 6,262,085
1036	U.S. Patent Pub. No. 2001/0000468
1037	U.S. Patent No. 5,051,262
1038	“Effects of Misoprostol on Gastric Acid and Mucus Secretion in Man,” Donald E. Wilson, et al., Digestive Diseases and Sciences, Vol. 31, No. 2 (Feb. 1986)
1039	“Measurement of Gastrointestinal pH Profiles in Normal Ambulant Human Subjects,” D. F. Evans, et al., Gut, Vol. 29, Issue 8 (Aug. 1988) (“Evans”)
1040	“Omeprazole,” Stephen P. Clissold, et al., Drugs, Vol. 32, Issue 1 (July 1986) (“Clissold”)

Exhibit No.	Description
1041	“Development of an Oral Formulation of Omeprazole,” A. Pilbrant, Scandinavian Journal of Gastroenterology, Vol. 20, No. s108 (1985) (“Pilbrant”)
1042	“Effects of Single and Repeated Doses of Omeprazole on Gastric Acid and Pepsin Secretion in Man,” C. W. Howden, et al., Gut, Vol. 25, Issue 7 (July 1984) (“Howden”)
1043	“Omeprazole: A Study of Its Inhibition of Gastric pH and Oral Pharmacokinetics After Morning or Evening Dosage,” Peter J. Prichard, et al., Gastroenterology, Vol. 88, Issue 1, Part 1 (Jan. 1985) (“Prichard”)
1044	“The Effects of Oral Doses of Lansoprazole and Omeprazole on Gastric pH,” Keith G. Tolman, et al., Journal of Clinical Gastroenterology, Vol. 24, Issue 2 (Mar. 1997) (“Tolman”)
1045	Citizen Petition, Horizon Pharma (Feb. 3, 2014)
1046	“Clinical Trial: Evaluation of Gastric Acid Suppression with Three Doses of Immediate-Release Esomeprazole in the Fixed-Dose Combination of PN 400 (Naproxen/Esomeprazole Magnesium) Compared with Naproxen 500 mg and Enteric-Coated Esomeprazole 20 mg: A Randomized, Open-Label, Phase I Study in Healthy Volunteers,” P. Miner, Jr., et al., Alimentary Pharmacology & Therapeutics, Vol. 32, Issue 3 (Aug. 2010) (“Miner”)
1047	FDA Response to Horizon’s Citizen Petition (July 3, 2014)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.